Company: ENTXW
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001178913-25-001674
Chunk: 84

Company: Entera Bio Ltd.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part II, Item 8
Chunk 84
---
 performed.

          NOTE 6 - SUBSEQUENT EVENTS

                  a.
                  
                    In April 2025, the Chairman of the board of directors exercised warrants for an aggregate of 23,952 ordinary shares for a total consideration of $24.

                    b.

                        On April 28, 2025, the board of directors approved the following options grants:

                    i.

                        options to purchase an aggregate of 954,000 ordinary shares were granted to employees, consultants and an executive officer with an exercise price of $2.28 per share which was the closing share price on the grant date; and

                  ii.
                  
                    options to purchase an aggregate of 830,000 ordinary shares were granted to several executive officers with an exercise price of $2.28 per share which was the closing share price on the grant date. These grants are subject to shareholders' approval.

            These options vest over three years from the date of grant; 33.33% vest on the first anniversary of the date of grant and the remaining 66.67% of the options will vest in eight equal quarterly installments following the first anniversary of the grant date.

                  iii.
                  
                    In addition, the board of directors approved the grant of 259,650 RSUs to executive officers (or entities controlled by such executive officers) in lieu of an annual cash bonus and partial cash salary increase, of which 233,334 RSUs are subject to shareholders' approval. The RSUs vest in four equal quarterly installments over a one-year period that started on April 28, 2025.

          14

                  ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                   
                  The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations, financial condition, liquidity and cash flows for the periods presented below. This discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and related notes contained elsewhere in this Quarterly Report, Part II, Item 1A-Risk Factors in this Quarterly Report, and Part I, Item 1A-Risk Factors in our 2024 Annual Report. As discussed in the section above titled “Cautionary Note Regarding Forward-Looking Statements,” the following discussion contains forward-looking statements that are based upon our current expectations, including with respect to our future operations, revenues and operating results. Our actual results may differ materially from those anticipated in such forward-looking